We have located links that may give you full text access.
Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
Clinical Drug Investigation 2019 Februrary
BACKGROUND AND OBJECTIVE: Empagliflozin and canagliflozin decreased the risk of major adverse cardiovascular events (MACE) compared with placebo in randomized clinical trials which were conducted to evaluate their cardiovascular risks. However, canagliflozin increased the risks of amputation and bone fracture, and the reasons for these observed differences remain unclear. The objective of this study was to evaluate the safety risks, specifically the risks of amputation and bone fracture, associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors by using the difference in restricted mean survival time (RMST), an alternative measure to the hazard ratio.
METHODS: This study included all the randomized clinical trials with cardiovascular events as a primary endpoint, comparing SGLT2 inhibitors with placebo in patients with type 2 diabetes mellitus, the results of which have been published as of 11 September 2018: EMPA-REG OUTCOME (empagliflozin) and CANVAS Program (canagliflozin). We reevaluated these trials by estimating RMSTs based on the reconstructed individual patient data for each time-to-event outcome from publicly available information.
RESULTS: The differences of RMSTs (SGLT2 inhibitors minus placebo: point estimate and 95% confidence interval) for lower-extremity amputations and low-trauma fracture were - 20 days (- 30, - 10) and - 15 days (- 30, 0), respectively, in CANVAS Program (2190 days follow-up). That for lower-limb amputation was 1 day (- 6, 8) in EMPA-REG OUTCOME (1440 days follow-up). Regarding the MACE, both empagliflozin and canagliflozin statistically significantly decreased the risk compared with placebo.
CONCLUSIONS: Canagliflozin was shown to increase the risks of amputation and bone fracture compared with placebo when using the difference in RMST.
METHODS: This study included all the randomized clinical trials with cardiovascular events as a primary endpoint, comparing SGLT2 inhibitors with placebo in patients with type 2 diabetes mellitus, the results of which have been published as of 11 September 2018: EMPA-REG OUTCOME (empagliflozin) and CANVAS Program (canagliflozin). We reevaluated these trials by estimating RMSTs based on the reconstructed individual patient data for each time-to-event outcome from publicly available information.
RESULTS: The differences of RMSTs (SGLT2 inhibitors minus placebo: point estimate and 95% confidence interval) for lower-extremity amputations and low-trauma fracture were - 20 days (- 30, - 10) and - 15 days (- 30, 0), respectively, in CANVAS Program (2190 days follow-up). That for lower-limb amputation was 1 day (- 6, 8) in EMPA-REG OUTCOME (1440 days follow-up). Regarding the MACE, both empagliflozin and canagliflozin statistically significantly decreased the risk compared with placebo.
CONCLUSIONS: Canagliflozin was shown to increase the risks of amputation and bone fracture compared with placebo when using the difference in RMST.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app